Table 5

Comparison of responders versus non-responders with regard to cancer type, gender, prior treatment history, stage at diagnosis and baseline 25(OH)D levels (N = 799)

Characteristic

Responders (n = 441)

Non-responders (n = 358)

Chi-square

p-value

Cancer Site

Breast

103 (56.6)

79 (43.4)

Lung

83 (69.2)

37 (30.8)

Pancreas

28 (46.7)

32 (53.3)

< 0.001

Colorectal

42 (46.7)

48 (53.3)

Prostate

42 (70)

18 (30)

Others

143 (49.8)

144 (50.2)

Gender

Males

153 (57.5)

113 (42.5)

0.35

Females

288 (54.0)

245 (46.0)

Treatment History

Newly Diagnosed

233 (56.8)

177 (43.2)

0.34

Previously Treated

208 (53.5)

181 (46.5)

Stage at Diagnosis

Stage 0

3 (37.5)

5 (62.5)

Stage 1

56 (52.8)

50 (47.2)

Stage 2

91 (55.5)

73 (44.5)

0.82

Stage 3

117 (56.3)

91 (43.8)

Stage 4

139 (57)

105 (43)

Indeterminate

35 (55.2)

34 (44.8)

Baseline serum 25(OH)D

< 12 ng/ml

55 (35.3)

101 (64.7)

12-20 ng/ml

145 (55.1)

118 (44.9)

< 0.001

20-32 ng/ml

241 (63.4)

139 (36.6)

Numbers in parenthesis are row percentages

Vashi et al. Nutrition Journal 2010 9:60   doi:10.1186/1475-2891-9-60